Ionis Pharmaceuticals, Inc.
IONS
$33.53
$1.273.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -7.64% | -10.48% | 30.57% | 29.00% | 34.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.64% | -10.48% | 30.57% | 29.00% | 34.84% |
| Cost of Revenue | -3.00% | -0.34% | -4.70% | -1.66% | 4.28% |
| Gross Profit | -22.36% | -65.56% | 67.38% | 66.66% | 53.38% |
| SG&A Expenses | 31.53% | 29.14% | 13.34% | 41.26% | 40.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.84% | 5.25% | -1.47% | 5.11% | 9.87% |
| Operating Income | -28.00% | -42.36% | 36.94% | 26.83% | 20.94% |
| Income Before Tax | -27.60% | -37.76% | 5.25% | -25.25% | -18.54% |
| Income Tax Expenses | -129.17% | -119.10% | -91.12% | -52.05% | -4.58% |
| Earnings from Continuing Operations | -19.04% | -23.92% | 12.37% | -18.35% | -16.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.04% | -23.92% | 12.37% | -18.35% | -16.99% |
| EBIT | -28.00% | -42.36% | 36.94% | 26.83% | 20.94% |
| EBITDA | -29.36% | -44.33% | 37.69% | 27.28% | 21.03% |
| EPS Basic | -11.81% | -18.79% | 14.66% | -16.65% | -15.45% |
| Normalized Basic EPS | -24.57% | -40.45% | 39.68% | 27.98% | 27.37% |
| EPS Diluted | -11.81% | -18.79% | 14.66% | -16.65% | -15.45% |
| Normalized Diluted EPS | -24.57% | -40.45% | 39.68% | 27.98% | 27.37% |
| Average Basic Shares Outstanding | 6.13% | 4.35% | 2.27% | 1.58% | 1.31% |
| Average Diluted Shares Outstanding | 6.13% | 4.35% | 2.27% | 1.58% | 1.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |